+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 50Years
All Genders
Healthy Volunteers
ID05961059

Safety and Immune Response Study of Shigella Flexneri 2a Vaccine with and without DmLT Adjuvant in Healthy Adults in the Netherlands and Zambia

Led by Leiden University Medical Center · Updated on 2024-11-07

85

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new injectable Shigella vaccine called InvaplexAR-Detox, combined with a new adjuvant dmLT, in healthy adults aged 18 to 50 years. The study aims to assess whether the vaccine, with or without the adjuvant, is safe, well tolerated, and able to stimulate the immune system effectively. This phase Iab trial involves healthy volunteers from the Netherlands and Zambia and addresses the challenge of improving immune responses to Shigella vaccines, especially in populations susceptible to this infection. Participants will receive three intramuscular vaccinations spaced 28 days apart. The study includes different groups receiving either low 2.5 g or high 10 g doses of the vaccine, with or without 0.1 g of the dmLT adjuvant, or a placebo saline. The trial begins with the lower dose in the Netherlands, progressing to higher doses after safety reviews. Similar dosing is also given to Zambian participants, allowing comparison across doses and locations. During the study, participants will undergo regular safety monitoring for adverse events within days following each vaccination. Researchers will also measure immune responses by testing blood samples for antibodies and cellular immune activity at multiple time points up to about 7 months after the first dose. Participants must complete all study visits and procedures, which include stool testing for Shigella and pregnancy testing for women of childbearing potential. The study is designed to carefully track safety and immune responses to better understand the vaccines potential.

CONDITIONS

Brief Title

InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia

Research Team

M

Meta Roestenberg, MD, PhD

M

Maxim Bax, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here